Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for cancer and other serious diseases. Founded in 2010, Karyopharm has made significant strides in the industry, particularly with its flagship product, XPOVIO (selinexor), which targets the nuclear export protein XPO1 to enhance cancer treatment efficacy. With a strong presence in the oncology sector, Karyopharm is dedicated to addressing unmet medical needs through its unique approach to drug development. The company has achieved notable milestones, including regulatory approvals and partnerships that bolster its market position. Karyopharm's commitment to advancing therapeutic options underscores its role as a key player in the biopharmaceutical landscape, striving to improve patient outcomes globally.
DitchCarbon Score
How does Karyopharm Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Karyopharm Therapeutics Inc.'s score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Karyopharm Therapeutics Inc.'s reported carbon emissions
Karyopharm Therapeutics Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Consequently, there are no documented reduction targets or climate commitments available from the company. As of now, Karyopharm has not inherited any emissions data from a parent or related organization, nor does it have any established science-based targets (SBTi) or other climate initiatives. This lack of data suggests that Karyopharm may still be in the early stages of developing a comprehensive climate strategy. In the broader context of the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and are setting ambitious targets to reduce their carbon footprints. However, without specific commitments or data, Karyopharm's position in this regard remains unclear.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Karyopharm Therapeutics Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
